Table 1.
Clinical characteristics of females with COVID-19
| Mild (n = 147) | Severe (n = 90) | P-value | |
|---|---|---|---|
| Age, years, median (IQR) | 36.00 (31.00–41.00) | 37.00 (32.75–41.00) | 0.13 |
| Comorbidities | |||
| Hypertension | 4 (3) | 6 (7) | 0.19 |
| Diabetes | 2 (1) | 7 (8) | 0.029 |
| Lung diseases | 2 (1) | 4 (4) | 0.20 |
| Cardiovascular disease | 3 (2) | 1 (1) | 1.00 |
| Kidney disease | 0 (0) | 2 (2) | 0.14 |
| Hepatic disease | 1 (1) | 5 (6) | 0.031 |
| Malignant tumour | 0 (0) | 6 (7) | 0.003 |
| Total | 12 (8) | 31 (34) | <0.001 |
| Signs and symptoms at disease onset | |||
| No symptoms | 9 (6) | 8 (9) | 0.42 |
| Fever | 105 (71) | 58 (64) | 0.26 |
| Cough | 83 (56) | 48 (53) | 0.64 |
| Sputum production | 62 (42) | 31 (34) | 0.24 |
| Diarrhoea | 27 (18) | 11 (12) | 0.21 |
| Chest tightness | 23 (16) | 6 (7) | 0.041 |
| Dyspnoea | 40 (27) | 20 (22) | 0.39 |
| Fatigue | 24 (16) | 14 (16) | 0.88 |
| Another | 41 (28) | 25 (28) | 0.99 |
| Death rate | 0 (0) | 3 (3) | 0.05 |
| Complications | |||
| Abnormal hepatic function | 5 (3) | 6 (7) | 0.34 |
| Abnormal renal function | 4 (3) | 4 (4) | 0.48 |
| Cardiac function injury | 14 (10) | 16 (18) | 0.06 |
| Digestive system injury | 29 (20) | 23 (26) | 0.29 |
| Respiratory system injury | 96 (65) | 66 (73) | 0.20 |
| Nervous system injury | 0 (0) | 8 (9) | <0.001 |
| Treatments | |||
| Antiviral therapy | 132 (90) | 74 (82) | 0.09 |
| Antibiotics | 99 (67) | 56 (62) | 0.42 |
| Glucocorticoid therapy | 38 (26) | 26 (29) | 0.61 |
| Intravenous immunoglobulin therapy | 19 (13) | 20 (22) | 0.06 |
| Oxygen treatment | |||
| High flow nasal cannula | 96 (65) | 59 (66) | 0.97 |
| Mechanical ventilation | 0 (0) | 7 (7) | 0.001 |
Data are presented as n (%) unless otherwise stated.